Original Source(s)
Related Content
FDA Clears Golimumab Biosimilars
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026
-
2 min
Antibiotic Falls Short in Disc-Related Back Pain
A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.
May 28, 2026
-
5 min